<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71969">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168829</url>
  </required_header>
  <id_info>
    <org_study_id>327494</org_study_id>
    <nct_id>NCT02168829</nct_id>
  </id_info>
  <brief_title>Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial</brief_title>
  <acronym>OCEAN</acronym>
  <official_title>The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is comparing medical approaches for stroke prevention in people who have atrial
      fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or
      substantially reduce the arrhythmia. AF is normally associated with an increased risk of
      stroke which in many patients can be prevented with appropriate blood thinner therapy. This
      trial will compare a strategy of oral anticoagulant therapy after successful ablation to
      therapy with an aspirin per day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, randomized trial to investigate whether a strategy of
      ongoing, long-term oral anticoagulation with rivaroxaban 15 mg daily is superior to a
      strategy of antiplatelet therapy, ASA 75-160 mg, alone in preventing cerebral embolic events
      in moderately high risk patients following successful catheter ablation for atrial
      fibrillation..

      At least one year post-successful catheter ablation for AF or left atrial
      flutter/tachycardia without evidence of any clinically apparent arrhythmia recurrence based
      on at least one 24 hour Holter and ECG within 6 months after the last ablation procedure and
      at least one 24 hour Holter and ECG between 6 and 12 months post-ablation or beyond. Patient
      must have no atrial fibrillation, atrial flutter or atrial tachycardia &gt; 30 seconds detected
      on a minimum 48 hour Holter monitor within two months prior to enrollment.

      Patients will be randomized in a 1:1 fashion to ASA 75-160 mg daily or rivaroxaban 15 mg
      daily. Patients will be seen at 6 months, one year and every year thereafter for a minimum
      of 3 years. Blood chemistry tests, ECG, holters and patient quality of life questionnaires
      will be done annually.

      Cerebral MRI scanning at baseline, at year one and at three years will be done for
      assessment of silent cerebral infarction. MRI imaging will be performed using a specific
      protocol.

      A pre-specified subset of patients will undergo insertion of a implantable loop recorder
      (ILR) capable of automated AF detection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of stroke, systemic embolism and covert embolic stroke as detected by cerebral MRI</measure>
    <time_frame>3 years</time_frame>
    <description>Composite of stroke, systemic embolism and covert embolic stroke as detected by cerebral MRI. A patient will be considered to have a covert stroke if one or more lesions &gt; 15 mm has been detected between the baseline, the one year and final (3 year) MRI on T2 weighted and/or FLAIR imaging protocols.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical, overt stroke</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinical, Overt stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of one or more covert MRI stroke(s) &gt;15 mm</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Incidence of one or more covert MRI stroke(s) &gt;15 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all major and minor bleeding</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Composite of all major and minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding only</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Major bleeding only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor bleeding only</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Minor bleeding only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Intracranial hemorrhage (clinical and covert on MRI alone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Transient ischemic attack defined as presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting &lt;24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net clinical benefit based on reduction in stroke/TIA rate compared to major bleeding events.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Net clinical benefit based on reduction in stroke/TIA rate compared to major bleeding events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of non-primary endpoint MRI changes from baseline to final scan</measure>
    <time_frame>3 years</time_frame>
    <description>Occurrence of non-primary endpoint MRI changes from baseline to final scan including: quantification of cerebral atrophy, quantification of cerebral white matter changes, number of all new MRI lesions &gt; 3mm, &gt;5 mm, &gt; 15 mm, and &gt; 20 mm, and number of lesions detected exclusively on DW-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological testing</measure>
    <time_frame>3 years</time_frame>
    <description>Neuropsychological testing - performed at baseline and repeated at 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
    <time_frame>3 years</time_frame>
    <description>Cost utilization and cost effectiveness analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1452</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivaroxaban 15 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid (ASA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <arm_group_label>Acetylsalicylic acid (ASA)</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least one year post-successful catheter ablation for AF or left atrial
             flutter/tachycardia without evidence of any clinically apparent arrhythmia recurrence
             based on at least one 24 hour Holter and ECG within 6 months after the last ablation
             procedure and at least one 24 hour Holter and ECG between 6 and 12 months
             post-ablation or beyond.

          2. Patient must have no atrial fibrillation, atrial flutter or atrial tachycardia &gt; 30
             seconds detected on a minimum 48 hour Holter monitor within two months prior to
             enrollment.

          3. CHA2DS2-VASc risk score of 1 or more excluding patients in whom female sex or
             vascular disease are their sole risk factor.

          4. Patients must be &gt; 18 years of age.

        Exclusion Criteria

          1. does not meet all of the above listed inclusion criteria.

          2. unable or unwilling to provide informed consent.

          3. included in another clinical trial

          4. GFR &lt; 30 mL/min

          5. contraindication to oral anticoagulation (OAC)

          6. contraindication to magnetic resonance imaging (MRI)

          7. metallic prosthetic heart valve

          8. non-arrhythmic condition necessitating long-term OAC

          9. stroke within one year prior to enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southlake Regional Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David H Birnie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David H Birnie, MD</last_name>
    <phone>613-761-4705</phone>
    <email>dbirnie@ottawaheart.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Russell D Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Wyse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian/Fraser Clinical Trials</name>
      <address>
        <city>New West Minster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>J.P. LeMaitre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc Deyell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jason Andrade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Leather, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ratika Parkash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlos Morillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Damian Redfearn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Allan Skanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Atul Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Birnie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Iqwal Mangat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eugene Crystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital (UHN)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de L'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabelle Greiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Health Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Macle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitarie de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Champagne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Francois Roux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 18, 2016</lastchanged_date>
  <firstreceived_date>June 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF ablation</keyword>
  <keyword>Anticoagulation AF ablation</keyword>
  <keyword>Stroke prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
